<DOC>
	<DOCNO>NCT00489203</DOCNO>
	<brief_summary>RATIONALE : Beclomethasone dipropionate may effective prevent acute graft-versus-host disease patient undergoing stem cell transplant hematologic cancer . PURPOSE : This randomized phase II trial study well beclomethasone dipropionate work prevent acute graft-versus-host disease patient undergo donor stem cell transplant hematologic cancer .</brief_summary>
	<brief_title>Beclomethasone Dipropionate Preventing Acute Graft-Versus-Host Disease Patients Undergoing Donor Stem Cell Transplant Hematologic Cancer</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I. Assess efficacy oral BDP prevention acute GVHD allogeneic hematopoietic cell transplantation myeloablative conditioning regimen . OUTLINE : Patients randomize 1 2 treatment arm . ARM I : Patients receive oral beclomethasone dipropionate 4 time daily begin start condition regimen continue day 75 post-transplant . Patients also receive standard immunosuppressive regimen comprise tacrolimus methotrexate post-transplant . ARM II : Patients receive oral placebo 4 time daily begin start condition regimen continue day 75 post-transplant . Patients also receive standard immunosuppressive regimen comprise tacrolimus methotrexate post-transplant . In arm , treatment continue absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Graft v Host Disease</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Primary Myelofibrosis</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Acute</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Chronic</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Thrombocytosis</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic , Atypical , BCR-ABL Negative</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Hypereosinophilic Syndrome</mesh_term>
	<mesh_term>Thrombocythemia , Essential</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Myelomonocytic , Juvenile</mesh_term>
	<mesh_term>Myelodysplastic-Myeloproliferative Diseases</mesh_term>
	<mesh_term>Leukemia , Neutrophilic , Chronic</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Beclomethasone</mesh_term>
	<criteria>Inclusion Allogeneic HCT marrow growthfactor mobilize blood cell HLAA , B , C , DRB1 , HLADQB1allele match singleallele antigen mismatch related unrelated donor Use myeloablative pretransplant condition regimen &gt; 800 cGy total body irradiation cyclophosphamide , highdose busulfan cyclophosphamide Use methotrexate tacrolimus prevention GVHD allogeneic HCT Informed consent document sign Exclusion Cord blood transplant recipient Use T cell depletion rabbit antithymocyte globulin prevent acute GVHD Treatment rabbit antithymocyte globulin alemtuzumab within 3 month date HCT Participation another therapeutic trial primary endpoint relate acute GVHD Hospitalization begin pretransplant condition regimen preexist medical complication Glucocorticoid treatment prednisoneequivalent dose &gt; 0.2 mg/kg/day Known intolerance BDP Anticipated inability tolerate oral administration study drug tablet reason first two week HCT Body weight &lt; 35 kg ( lowerdose formulation available subject low body weight ) Pregnancy breast feed Women childbearing potential unwilling use reliable method contraception Incarceration</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
</DOC>